Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Medtronic recalls reflux monitoring devices after capsule failures

Medtronic recalls reflux monitoring devices after capsule failures

Rule Changes

FDA early alert ties 184 serious injuries to Bravo CF delivery device as second recall lands in 14 months

September 3rd, 2026: Recall draws broad press coverage

Overview

Updated Sep 4

The Bravo CF device attaches a pH-monitoring capsule to the esophagus so doctors can diagnose acid reflux. In 761 reported instances since early 2025, the capsule failed to attach or detach as intended, and 184 of those involved serious injuries.

Medtronic recalled the affected delivery devices in August, and the Food and Drug Administration urged hospitals to quarantine them. Failures can tear the esophagus, block the airway, or leave a foreign object inside the patient. It's the second recall for the same failure in 14 months, though the FDA says the root cause is different this time.

Why it matters

A capsule designed to stick to the esophagus can instead tear it or block the airway — with 184 serious injuries already reported.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

184
Serious injuries reported as of Aug 10, 2026
Injuries among 761 complaints of capsule attach/detach failure between Jan 2025 and July 2026.
761
Capsule failure complaints
Failures reported to Medtronic between Jan 1, 2025 and July 7, 2026.
0
Deaths linked to the failure
No deaths reported as of August 10, 2026.
2
Recalls in 14 months
June 2025 adhesive defect recall and August 2026 deployment-component recall.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Organizations Involved

Medtronic plc
Medtronic plc
Medical device manufacturer
Recalling Bravo CF capsule delivery devices; issuing replacements

Makes the Bravo pH-monitoring system through its Given Imaging subsidiary.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Issued early alerts; classified June 2025 recall as Class I

Regulates medical devices, issues recalls and early alerts, and classifies severity of device problems.

Timeline

June 2025 September 2026

7 events Latest: September 3rd, 2026 · 1 week ago
Tap a bar to jump to that date

  1. Recall draws broad press coverage

    Latest Media

    Fierce Biotech and other outlets report the recall, spreading the FDA alert widely.

  2. Injury count hits 184

    Data

    Medtronic reports 184 serious injuries and no deaths to the FDA.

  3. Second recall for deployment failure

    Recal

    Medtronic issues second recall letter citing a deployment-component fault; 184 injuries now reported.

  4. First recall called Class I

    Regulatory

    FDA classifies the June 2025 recall as Class I, its most serious device-recall category.

  5. FDA issues early alert

    Regulatory

    FDA notifies the public of a potentially high-risk device issue with Bravo CF delivery devices.

  6. Updated recall letter sent

    Recal

    Medtronic sends an updated letter to customers and distributors about the affected devices.

  7. First recall over adhesive defect

    Recal

    Medtronic sends URGENT recall letter citing adhesive misapplication during manufacturing; 33 serious injuries reported.

Scenarios

1

Recalled devices recovered, no new injuries reported

Likely Resolves by Q2 2027

Discussed by: Medtronic's recall letter, which instructs customers to return unused devices for replacement

Medtronic retrieves affected lots, ships replacements, and hospitals resume normal use. The FDA closes the early alert once the deployment-component problem is confirmed fixed. This is the outcome the recall is designed to produce.

2

Recall expands to additional lots

Possible Resolves by Q1 2027

Discussed by: Medtronic's Aug 6 letter, which excluded lots expiring on or after Dec 10, 2027

If the deployment-component failure shows up in lots currently excluded from the recall, Medtronic widens the scope. The underlying cause may surface in more devices as testing continues. The FDA would issue another recall notice.

3

Litigation and regulatory penalties mount

Possible Resolves by End of 2027

Discussed by: Medical device legal trackers

With 184 serious injuries reported, plaintiffs' firms may file suits against Medtronic. The FDA could impose penalties or require corrective actions beyond device replacement. Medtronic's securities filings would reveal material litigation as it develops.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2005-2006

Guidant defibrillator recalls (2005-2006)

Guidant recalled heart defibrillators after discovering short-circuit failures that could stop the devices from delivering lifesaving shocks. The recall began with a narrow set of models and expanded to more.

Then

Guidant faced lawsuits and sharp FDA scrutiny over how it disclosed the failures.

Now

The case set precedents for timely disclosure of device failures to doctors and patients.

Why this matters now

Bravo CF mirrors the pattern of repeated recalls for the same underlying device, with the FDA pressing for faster disclosure each time.

June 2021 onward

Philips Respironics CPAP recall (2021)

Philips recalled millions of CPAP and ventilator devices in June 2021 because sound-abating foam degraded and could be inhaled by patients. The recall expanded over years and drew a consent decree with the FDA in 2024.

Then

Philips set aside billions of dollars for recalls and settled with affected patients; the FDA required a structured remediation plan.

Now

The case shows how a single device failure can cascade into years of regulatory and legal fallout.

Why this matters now

Like Philips, Medtronic faces a device whose failure mode harms patients in a way the original design was meant to prevent.

Sources

(9)
+3
U.S. Food and Drug Administration MedTech Dive Fierce Biotech Minnesota Star Tribune PharmaDeviceNews Life Science Nordic U.S. Food and Drug Administration Medindia U.S. Food and Drug Administration